The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma
Abstract
Purpose: Bleomycin pulmonary toxicity (BPT) has been well described in Hodgkin's lymphoma (HL) patients treated with bleomycin-containing chemotherapy regimens. The influence of this pulmonary complication, along with the omission of bleomycin from further chemotherapy, on overall survival (OS) and progression-free survival (PFS) in HL remains unclear. We reviewed our experience with BPT in HL to better delineate outcome and appropriate treatment in these patients. Patients and Methods: One hundred forty-one patients who were treated with bleomycin-containing chemotherapy for newly diagnosed HL between January 1986 and February 2003 were eligible for this retrospective review. BPT was defined by the presence of pulmonary symptoms, bilateral interstitial infiltrates, and no evidence of an infectious etiology. Results: BPT was observed in 18% of patients. Increasing age, doxorubicin, bleomycin, vinblastine, and dacarbazine as initial therapy, and granulocyte colony-stimulating factor use were associated with the development of BPT. Patients with BPT had a median 5-year OS rate of 63% v 90% (P = .001) in unaffected patients. The mortality rate from BPT was 4.2% in all patients and 24% in patients who developed the pulmonary syndrome. BPT incidence and mortality were highest in patients older than 40 years. The omission of bleomycin had no impact on obtaining a complete remission, PFS, or OS. Conclusion: BPT results in a significant decrease in 5-year OS in patients who are treated for HL. Age ≥ 40 years seems to add substantially to the risk. In patients who do not die from acute pulmonary toxicity, both OS and PFS seem equal, despite the omission of bleomycin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Prognostic Score for Advanced Hodgkin's Disease
Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Björkholm, M., Brusamolino, E., Canellos, G. P., Carde, P., Crowther, D., Cunningham, D., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392104 · Cited by 1,736
Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD
Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., & Peterson, B. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211193272102 · Cited by 1,148
A clinical review of bleomycin—a new antineoplastic agent
Blum, R. H., Carter, S. K., & Agre, K. (1973) · Cancer · doi:10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n · Cited by 864
Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.-K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022473 · Cited by 838
Sleijfer, S. (2001) · Chest · doi:10.1378/chest.120.2.617 · Cited by 611
Duggan, D. B., Petroni, G. R., Johnson, J. L., Glick, J. H., Fisher, R. I., Connors, J. M., Canellos, G. P., & Peterson, B. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.086 · Cited by 487
Horning, S. J., Hoppe, R. T., Breslin, S., Bartlett, N. L., Brown, B. W., & Rosenberg, S. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.630 · Cited by 324
Umezawa, H., Ishizuka, M., Maeda, K., & Takeuchi, T. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:5<891::aid-cncr2820200550>3.0.co;2-v · Cited by 189
Clinical trials with bleomycin in lymphomas and in solid tumors
Bonadonna, G., Lena, M. D., Monfardini, S., Bartoli, C., Bajetta, E., Beretta, G., & Fossati‐Bellani, F. (1972) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(72)90045-x · Cited by 93
Azoulay, É., Hérigault, S., Levame, M., Brochard, L. J., Schlemmer, B., HARF, A., & Delclaux, C. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050453.28177.33 · Cited by 66
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d’Amore, F., Enblad, G., Franceschetto, A., Fulham, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510093 · Cited by 818
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708984 · Cited by 789
Self-citationCysteine/cystine redox signaling in cardiovascular disease
Go, Y.-M., & Jones, D. P. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.11.029 · Cited by 447
How I monitor long-term and late effects after blood or marrow transplantation
Bhatia, S., Armenian, S. H., & Landier, W. (2017) · Blood · doi:10.1182/blood-2017-03-725671 · Cited by 66
Metadata
- Authors
- Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E., & Ansell, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-20
- Volume
- 23
- Issue
- 30
- Pages
- 7614-7620
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2105259666
- Cited by
- 302
- References
- 10
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.